Clinical Trials
Rilvegostomig + Bevacizumab w/or w/o Tremelimumab as First Line treatment in advanced Hepatocellular Carcinoma
Disease Type: Hepatocellular
A Phase III, Randomized, Open-label, Sponsor-blinded, Multicentre Study of Rilvegostomig in Combination with Bevacizumab with or without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Locations
Alleghany , Blacksburg , Roanoke , Salem , Wytheville